Although increased Oct4 expression is associated with enhanced resistance to chemo-, radio-, and targeted therapies, Oct4 knockdown sensitizes glioma cells to treatment with temozolomide chemotherapy (Ikushima et al., 2011; Mohiuddin et al., 2019). The gene discussed is POU5F1; the disease is central nervous system cancer.